Literature DB >> 18453369

Cardiac disease in chronic obstructive pulmonary disease.

Jeremy A Falk1, Steven Kadiev, Gerard J Criner, Steven M Scharf, Omar A Minai, Philip Diaz.   

Abstract

The cardiac manifestations of chronic obstructive pulmonary disease (COPD) are numerous. Impairments of right ventricular dysfunction and pulmonary vascular disease are well known to complicate the clinical course of COPD and correlate inversely with survival. The pathogenesis of pulmonary vascular disease in COPD is likely multifactorial and related to alterations in gas exchange and vascular biology, as well as structural changes of the pulmonary vasculature and mechanical factors. Several modalities currently exist for the assessment of pulmonary vascular disease in COPD, but right heart catheterization remains the gold standard. Although no specific therapy other than oxygen has been generally accepted for the treatment of pulmonary hypertension in this population, there has been renewed interest in specific pulmonary vasodilators. The coexistence of COPD and coronary artery disease occurs frequently. This association is likely related to shared risk factors as well as similar pathogenic mechanisms, such as systemic inflammation. Management strategies for the care of patients with COPD and coronary artery disease are similar to those without COPD, but care must be given to address their respiratory limitations. Arrhythmias occur frequently in patients with COPD, but are rarely fatal and can generally be treated medically. Use of beta-blockers in the management of cardiac disease, while a theoretical concern in patients with increased airway resistance, is generally safe with the use of cardioselective agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453369      PMCID: PMC2645333          DOI: 10.1513/pats.200708-142ET

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  102 in total

1.  Effect of lung volume reduction surgery for severe emphysema on right ventricular function.

Authors:  Tommaso C Mineo; Eugenio Pompeo; Paola Rogliani; Mario Dauri; Franco Turani; Patrizio Bollero; Natalia Magliocchetti
Journal:  Am J Respir Crit Care Med       Date:  2002-02-15       Impact factor: 21.405

2.  Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Ann Intern Med       Date:  2002-11-05       Impact factor: 25.391

3.  Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease.

Authors:  Malcolm I Burgess; Nesrin Mogulkoc; Rowland J Bright-Thomas; Paul Bishop; Jim J Egan; Simon G Ray
Journal:  J Am Soc Echocardiogr       Date:  2002-06       Impact factor: 5.251

4.  Variation in mortality risk factors with time after coronary artery bypass graft operation.

Authors:  Dexiang Gao; Gary K Grunwald; John S Rumsfeld; Todd Mackenzie; Frederick L Grover; Jonathan B Perlin; Gerald O McDonald; A Laurie W Shroyer
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

Review 5.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

6.  Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers.

Authors:  J A Barberà; V I Peinado; S Santos; J Ramirez; J Roca; R Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

7.  Discontinuation of furosemide decreases PaCO(2) in patients with COPD.

Authors:  Folkert Brijker; Yvonne F Heijdra; Frank J J van den Elshout; Hans Th M Folgering
Journal:  Chest       Date:  2002-02       Impact factor: 9.410

8.  brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure.

Authors:  Stefan Krüger; Jürgen Graf; Dagmar Kunz; Tina Stickel; Peter Hanrath; Uwe Janssens
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

9.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.

Authors:  Eugene Kotlyar; Anne M Keogh; Peter S Macdonald; Ruth H Arnold; Dermot J McCaffrey; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2002-12       Impact factor: 10.247

10.  Hemodynamic characterization of patients with severe emphysema.

Authors:  Steven M Scharf; Mobeen Iqbal; Cesar Keller; Gerald Criner; Shing Lee; Henry E Fessler
Journal:  Am J Respir Crit Care Med       Date:  2002-08-01       Impact factor: 21.405

View more
  51 in total

Review 1.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Pulmonary hypertension in a stable community-based COPD population.

Authors:  Vadim Fayngersh; Fotios Drakopanagiotakis; F Dennis McCool; James R Klinger
Journal:  Lung       Date:  2011-08-04       Impact factor: 2.584

3.  Arterial and Venous Pulmonary Vascular Morphology and Their Relationship to Findings in Cardiac Magnetic Resonance Imaging in Smokers.

Authors:  Farbod N Rahaghi; J Michael Wells; Carolyn E Come; Isaac A De La Bruere; Surya P Bhatt; James C Ross; Gonzalo Vegas-Sánchez-Ferrero; Alejandro A Diaz; Jasleen Minhas; Mark T Dransfield; Raúl San José Estépar; George R Washko
Journal:  J Comput Assist Tomogr       Date:  2016 Nov/Dec       Impact factor: 1.826

4.  Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

Authors:  Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

5.  Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias.

Authors:  Kathrin Weidner; Michael Behnes; Jonas Rusnak; Gabriel Taton; Tobias Schupp; Linda Reiser; Armin Bollow; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Philip Kuche; Jorge Hoppner; Ibrahim El-Battrawy; Siegfried Lang; Christoph A Nienaber; Kambis Mashayekhi; Dennis Ferdinand; Christel Weiß; Martin Borggrefe; Ibrahim Akin
Journal:  Cardiol J       Date:  2018-12-19       Impact factor: 2.737

6.  Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Hossein A Ghofrani; Gerd Staehler; Ekkehard Grünig; Michael Halank; Veselin Mitrovic; Sigrun Unger; Wolfgang Mueck; Reiner Frey; Friedrich Grimminger; Ralph T Schermuly; Juergen Behr
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

7.  Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD.

Authors:  Tadahiro Goto; Yuichi J Shimada; Mohammad Kamal Faridi; Carlos A Camargo; Kohei Hasegawa
Journal:  J Gen Intern Med       Date:  2018-06-08       Impact factor: 5.128

8.  Early and Long-term Outcomes of Older Adults after Acute Care Encounters for Chronic Obstructive Pulmonary Disease Exacerbation.

Authors:  Liza Genao; Michael T Durheim; Xiaojuan Mi; Jamie L Todd; Heather E Whitson; Lesley H Curtis
Journal:  Ann Am Thorac Soc       Date:  2015-12

9.  Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia.

Authors:  Cynthia Ashley; Danielle Burton; Yrsa B Sverrisdottir; Mikael Sander; David K McKenzie; Vaughan G Macefield
Journal:  J Physiol       Date:  2010-01-05       Impact factor: 5.182

10.  The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings.

Authors:  Javier de Miguel-Díez; Pilar Carrasco-Garrido; Javier Rejas-Gutierrez; Antonio Martín-Centeno; Elena Gobartt-Vázquez; Valentín Hernandez-Barrera; Angel Gil de Miguel; Rodrigo Jimenez-Garcia
Journal:  BMC Cardiovasc Disord       Date:  2010-02-18       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.